Brokerages Set Teva Pharmaceutical Industries Limited (NYSE:TEVA) Price Target at $18.89

Teva Pharmaceutical Industries Limited (NYSE:TEVA) has been given an average recommendation of “Moderate Buy” by the nine analysts that are covering the company, MarketBeat reports. Two investment analysts have rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 12 month target price among brokers that have covered the stock in the last year is $18.89.

A number of research analysts have weighed in on TEVA shares. StockNews.com raised shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 3rd. Bank of America raised their price target on Teva Pharmaceutical Industries from $18.00 to $21.00 and gave the company a “buy” rating in a research note on Thursday, May 30th. Argus upgraded Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $20.00 price target for the company in a report on Wednesday, July 10th. UBS Group upped their price objective on shares of Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a “buy” rating in a report on Tuesday, September 3rd. Finally, Barclays increased their target price on Teva Pharmaceutical Industries from $21.00 to $22.00 and gave the stock an “overweight” rating in a research note on Thursday, August 1st.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, insider Eric A. Hughes sold 24,537 shares of Teva Pharmaceutical Industries stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $17.25, for a total transaction of $423,263.25. Following the transaction, the insider now directly owns 45,060 shares of the company’s stock, valued at approximately $777,285. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Teva Pharmaceutical Industries news, Director Roberto Mignone sold 519,000 shares of the business’s stock in a transaction on Tuesday, June 18th. The stock was sold at an average price of $17.03, for a total value of $8,838,570.00. Following the transaction, the director now owns 981,000 shares of the company’s stock, valued at $16,706,430. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Eric A. Hughes sold 24,537 shares of the company’s stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $17.25, for a total value of $423,263.25. Following the completion of the transaction, the insider now owns 45,060 shares of the company’s stock, valued at approximately $777,285. The disclosure for this sale can be found here. Company insiders own 0.55% of the company’s stock.

Hedge Funds Weigh In On Teva Pharmaceutical Industries

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Victory Capital Management Inc. grew its stake in shares of Teva Pharmaceutical Industries by 21.9% during the 4th quarter. Victory Capital Management Inc. now owns 38,386 shares of the company’s stock worth $401,000 after acquiring an additional 6,886 shares during the period. Private Advisor Group LLC increased its stake in shares of Teva Pharmaceutical Industries by 31.5% in the fourth quarter. Private Advisor Group LLC now owns 19,424 shares of the company’s stock worth $204,000 after purchasing an additional 4,654 shares in the last quarter. BNP Paribas Financial Markets raised its position in shares of Teva Pharmaceutical Industries by 22.9% in the fourth quarter. BNP Paribas Financial Markets now owns 1,425,984 shares of the company’s stock valued at $14,887,000 after purchasing an additional 265,410 shares during the period. AGF Management Ltd. bought a new position in Teva Pharmaceutical Industries in the 4th quarter worth approximately $228,000. Finally, QRG Capital Management Inc. grew its stake in Teva Pharmaceutical Industries by 10.2% in the 4th quarter. QRG Capital Management Inc. now owns 93,500 shares of the company’s stock valued at $976,000 after buying an additional 8,680 shares in the last quarter. 54.05% of the stock is owned by hedge funds and other institutional investors.

Teva Pharmaceutical Industries Price Performance

Teva Pharmaceutical Industries stock opened at $18.02 on Tuesday. Teva Pharmaceutical Industries has a one year low of $8.06 and a one year high of $19.08. The company has a debt-to-equity ratio of 2.52, a current ratio of 0.89 and a quick ratio of 0.59. The business has a 50 day simple moving average of $17.49 and a 200 day simple moving average of $15.86. The company has a market capitalization of $20.41 billion, a PE ratio of -43.80, a price-to-earnings-growth ratio of 1.25 and a beta of 0.88.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings data on Wednesday, July 31st. The company reported $0.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.55 by $0.03. The firm had revenue of $4.16 billion for the quarter, compared to the consensus estimate of $3.99 billion. Teva Pharmaceutical Industries had a positive return on equity of 39.66% and a negative net margin of 2.73%. On average, sell-side analysts forecast that Teva Pharmaceutical Industries will post 2.35 EPS for the current fiscal year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.